Erschienen in:
01.08.2012 | Research Article
Recombinant human endostatin could eliminate the pro-angiogenesis priority of SP cells sorted from non-small cell lung cancer cells
verfasst von:
Baoshan Cao, Jun Jia, Liwen Ma, Lijun Di, Guohong Song, Yanhua Yuan, Bo Ma, Yulin Zhu, Jing Yu, Xiaoli Wang, Xinna Zhou, H. Kim Lyerly, Jun Ren
Erschienen in:
Clinical and Translational Oncology
|
Ausgabe 8/2012
Einloggen, um Zugang zu erhalten
Abstract
Purpose
To ascertain the biologic significance of lung cancer Side population (SP) cells, which represent putative cancer stem cells (CSC) in the absence of consensus biomarkers for tumor-specific CSC.
Materials and methods
We sorted and analyzed the angiogenic features of SP cells, isolated from tumor cell lines based on the exclusion of the DNA dye Hoechst 33342, from the NSCLC cell lines A549 and H460.
Results
Compared with non-SP cells, mRNA of vascular endothelial growth factor (VEGF)-A, VEGF-B, angiopoietin (ang)-1, ang-2, fibroblast growth factor-2 (FGF-2), cyclooxygenase-2 (Cox-2) and interleukin-8 (IL-8) were over-expressed in SP cells accompanied by over-expression of ABCG2 and MDR1 mRNA. The supernatant of cultured SP cells could significantly induce migration of human umbilical vein endothelial cells, while recombinant human endostatin (Endostar 25®) could inhibit the migration.
Conclusions
This study revealed that the NSCLC SP cells might represent CSCs and possess pro-angiogenic properties, and antiangiogenesis represent a potential therapy.